Nicox Announces Data Collection Complete, NCX 470 Phase 3b Whistler Glaucoma Trial

Nicox announced today that the last patient completed their final visit in the Whistler phase 3b clinical trial investigating the efficacy of NCX470 to lower IOP. This marks the end of their data collection period. 

NCX 470 (bimatoprost grenod) uses a dual mechanism of action—nitric oxide and a prostaglandin analog—to lower IOP. The Whistler phase 3b trial is a double-masked, placebo-controlled study that evaluated the effect of NCX470 on aqueous humor parameters such as trabecular meshwork outflow and episcleral venous pressure. In the study, 18 volunteers with ocular hypertension were enrolled, and each subject participated in the trial for approximately 8 days. 

Nicox stated they expect the results of this study in May 2025. Nicox’s second Denali phase 3 clinical trial has also completed their final patient visit in the U.S.; the trial is ongoing with patients in China, with results on track for later this year.